Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Staphylococcus aureus is a coccus, gram-positive, non-spore forming, and non-motile bacterium. Its commensal and opportunistic capabilities make it able to colonize different sites of animals and humans. Resistance to antibiotics has resulted in development of new strains and new types within strains. Types of methicillin-resistant S. aureus (MRSA) include hospital-acquired MRSA (HA-MRSA), community-acquired MRSA (CA-MRSA), and livestock-acquired MRSA (LA-MRSA). There are also new strains like vancomycin-resistant S. aureus (VRSA) and vancomycin-intermediate S. aureus (VISA). Expansion in resistance is expected to give rise to newer strains resistant to antibiotics such as macrolide (erm gene), tetracycline (tet genes), mupirocin (mupR), and fusidic acid (fusD). Alternative approaches like nanoparticles, bacteriophages, phytochemicals, and more are required to tackle this pathogen. This book contains information on epidemiology, resistance mechanisms, and alternative ways to curtail S. aureus infection, as well as future research opportunities.

Drug resistance.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drug Resistance

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drug Resistance. --- Drug Resistance. --- Epilepsy. --- Epilepsy.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple drug resistance among bacteria has become a global issue with a considerable impact on the mortality associated with infectious diseases. This book is a detailed compilation of available knowledge on the surveillance and mechanisms of antibiotic resistance in various countries throughout the world. Readers will be updated on current information on the understanding of mechanisms involved in drug resistance and the geographical distribution of resistance determinant markers. This volume should be a useful guide for microbiologists and clinicians interested in designing antimicrobial th

Multidrug resistance. --- Multi-drug resistance --- Multiple drug resistance --- Pleiotropic drug resistance --- Drug resistance

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

La réponse du monde scientifique face aux résistances croissantes des bactéries aux antibiotiques est de repenser le développement des antiinfectieux en appliquant un concept qui marche déjà dans d'autres domaines thérapeutiques tels que l'oncologie et la neurologie : les multi-targets drugs. De par son mécanismed'action multiple, elles permettent d'avoir une meilleure efficacité tout en diminuant l'apparition de résistance aux médicaments. Leur application dans le domaine infectieux est encore à ses débuts : les molécules issues de la recherche telle que le SQ109 n'en sont encore qu'aux études cliniques de phase II, mais leur profil plus sûr et leur efficacité, notamment dans le traitement de la tuberculose, ont déjà été démontrés. Le SQ109 inhibe de nombreuses cibles comme (1) la MmpL3, responsable du transport de acides mycoliques dans la paroi ; (2) le MenA et le MenG, enzymes de la synthèse de la ménaquinone ; (3 la « proton motive force » ; (4) des protéines de la chaine de transport d'électrons. C'est cette diversité dans les cibles qui lui confère son activité non seulement contre Mycobacterium tuberculosis, mais aussi contre d'autres bactéries, des champignons et même des protozoaires. The answer of the scientific community to the increasing resistance of the bacteria to the antibiotics is to rethink the development of anti-infectious drugs a field-proven concept from other therapeutic domains such as oncology and neurology: the multi-target drugs. Thanks to its multi-action mechanisms, they give a better efficiency while decreasing the occurrence of drug resistance. Their application in the infectious field is still at its beginning: research molecules such as the SQ109 are still in the phase I clinical trials, but their safer profile and their efficiency, especially in the treatment of the tuberculosis were already proven. The SQ109 inhibits multiple targets such as (1) the MmpL3, responsible for the mycolic acids transportation inside the wall; (2) the MenA and the MenG, enzyms of the menaquinon synthesis; (3) the proton motive force ; (4) the proteins in the electron transport chain. This diversity of targets gives the SQ109 its activity against Mycobacterium tuberculosis as well as against other bacteria’s fungi, and even protozoan.

Drug Resistance, Bacterial --- Tuberculosis